iMedicus Cardiology, presented by EOCI Pharmacomm, features short and engaging episodes for Canadian Health Care Professionals practicing in cardiology. Tune in for the latest on guidelines, current and emerging therapies, clinical pearls, and best practices, across a range of topics in Cardiology.
Current Challenges in Anticoagulating AF Patients with Renal Impairment
In this podcast, we are joined by Dr. Andrew Steele, nephrologist at Lakeridge Health. He discusses the efficacy and safety considerations in patients with atrial fibrillation and chronic kidney disease, Canadian recommendations for appropriate dosing of NOACs and how clinicians can limit the progression of renal impairment in their patients.
This program was made available through funding from Bayer.
16 Jul 2021
Updates to the CCS Dyslipidemia Guidelines: Application to Established CVD Patients
In this podcast, we are joined by Dr. Vineeta Ahooja, cardiologist in the greater Toronto area at the Heart Health Institute, and Dr. George Thanassoulis, cardiologist at McGill University Health Centre and Co-Chair of the 2021 Canadian Cardiovascular Society Dyslipidemia Guidelines. They discuss the use of ezetimibe and PCSK9i, including considerations around the costs of medications. When triglycerides are high, should icosapent ethyl or PCSK9i be considered first? Listen to find out!
This program was made available through funding from HLS Therapeutics.
18 Jun 2021
Current Dyslipidemia Management: What do the 2021 CCS Guidelines Say?
Welcome to the podcast series CAN-R3: Canadian Initiative to Reduce Residual Risk – Game Changers in Dyslipidemia Management. In this series, Canadian experts discuss the importance and challenges of reducing LDL-C in patients with established ASCVD, recommendations from the 2021 Canadian Cardiovascular Society Guidelines, and evidence around statins efficacy and adherence in different patient populations. Visit iMedicus.ca/Dyslipidemia to watch the Section 1 accredited webinars.
In this first episode, Dr. Judy Luu and Dr. Shaun Goodman exchange on the different contributors to residual risk, the role of LDL-C in atherosclerosis, the importance of reducing LDL-C as low as possible, identifying patients who benefit the most from intensification therapy beyond statins, and the shift to LDL-C thresholds as opposed to treatment targets.
Inside a recent episode
Current Challenges in Anticoagulating AF Patients with Renal Impairment
Published 16 Jul 2021 · Transcript excerpt
[…] So while the CCS and basically globally guidelines have recommended NOACs for the prevention of stroke in patients with age or fibrillation, many primary care physicians and even some specialists have been cautious when they're treating patients with CKD, especially advanced CKD. Nonetheless, we have a lot of evidence, both from the randomized clinical trials, such as the subset of patients in the rocket trial who had reduced renal function, as well as the other large cardiovascular outcome trials with the other available agents in Canada. And we have evidence in patients with more advanced CKD in stage four and even stage five CKD for stroke prevention with NOACs. […]
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
